{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:25:52Z","timestamp":1774340752902,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11606-022-07793-x","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T17:02:47Z","timestamp":1665680567000},"page":"881-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-3437","authenticated-orcid":false,"given":"Chelsea","family":"Richwine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Everson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"7793_CR1","unstructured":"Prescription Drug Abuse Policy System. PDMP Implementation Dates. Available from: https:\/\/pdaps.org\/datasets\/pdmp-implementation-dates."},{"key":"7793_CR2","unstructured":"SB603 Modifies provisions relating to the monitoring of certain controlled substances. SS SB 63; 2020. Available from: https:\/\/www.senate.mo.gov\/21info\/BTS_Web\/Bill.aspx?SessionType=R&BillID=54228843"},{"key":"7793_CR3","unstructured":"Prescription Drug Monitoring Program Training and Technical Assistance Center. Prescription Drug Monitoring Program. Mandatory Enrollment and Use of PDMPs. (July 2020). Available from: https:\/\/www.pdmpassist.org\/pdf\/TAG_Mandatory_Enrollment_Use_20200710.pdf"},{"key":"7793_CR4","unstructured":"Centers for Disease Control and Prevention. Prescription Drug Monitoring Programs (PDMPs): What States Need to Know. (May 2021). Available from: https:\/\/www.cdc.gov\/drugoverdose\/pdmp\/index.html"},{"key":"7793_CR5","unstructured":"National Center for Injury Prevention and Control (U.S.). Division of Unintentional Injury Prevention. Integrating & Expanding Prescription Drug Monitoring Program Data: Lessons from Nine States. (February 2017). Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/45241"},{"key":"7793_CR6","unstructured":"Davis C, Sargent W, Vick J, Kuoh H, Cote P-O. Leveraging Prescription Drug Monitoring Program (PDMP) Data in Overdose Prevention and Response. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/108523"},{"key":"7793_CR7","unstructured":"Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297-303."},{"key":"7793_CR8","doi-asserted-by":"crossref","unstructured":"Bao Y, Wen K, Johnson P, Jeng PJ, Meisel ZF, Schackman BR. Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions. Health Affairs. 2018;37(10):1596-604.","DOI":"10.1377\/hlthaff.2018.0512"},{"key":"7793_CR9","doi-asserted-by":"crossref","unstructured":"Grecu AM, Dave DM, Saffer H. Mandatory access prescription drug monitoring programs and prescription drug abuse. J Policy Anal Manage. 2019;38(1):181-209.","DOI":"10.1002\/pam.22098"},{"key":"7793_CR10","doi-asserted-by":"crossref","unstructured":"Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse Res Treat. 2009;3:SART. S2345.","DOI":"10.4137\/SART.S2345"},{"key":"7793_CR11","doi-asserted-by":"crossref","unstructured":"Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747-54.","DOI":"10.1111\/j.1526-4637.2011.01062.x"},{"key":"7793_CR12","doi-asserted-by":"crossref","unstructured":"Rhodes E, Wilson M, Robinson A, Hayden JA, Asbridge M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Serv Res. 2019;19(1):1-11.","DOI":"10.1186\/s12913-019-4642-8"},{"key":"7793_CR13","doi-asserted-by":"crossref","unstructured":"Heather DM, Modi SS, Feldman SS. Barriers and facilitators to PDMP IS Success in the US: a systematic review. Drug Alcohol Depend. 2020:108460.","DOI":"10.1016\/j.drugalcdep.2020.108460"},{"key":"7793_CR14","unstructured":"Pew Charitable Trusts. Prescription Drug Monitoring Programs: Evidence-Based Practices to Optimize Prescribers Use. (December 2016). Available from: https:\/\/www.pewtrusts.org\/~\/media\/assets\/2016\/12\/prescription_drug_monitoring_programs.pdf"},{"key":"7793_CR15","unstructured":"Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians\u2019 use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 2017;18(6):1063-9."},{"key":"7793_CR16","doi-asserted-by":"crossref","unstructured":"Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):1-8.","DOI":"10.1186\/s12913-017-2354-5"},{"key":"7793_CR17","doi-asserted-by":"crossref","unstructured":"Smith RJ, Kilaru AS, Perrone J, Paciotti B, Barg FK, Gadsden SM, et al. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Pain Med. 2015;16(6):1122-31.","DOI":"10.1111\/pme.12700"},{"key":"7793_CR18","doi-asserted-by":"crossref","unstructured":"Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. 2015;34(3):484-92.","DOI":"10.1377\/hlthaff.2014.1085"},{"key":"7793_CR19","doi-asserted-by":"crossref","unstructured":"Poon SJ, Greenwood-Ericksen MB, Gish RE, Neri PM, Takhar SS, Weiner SG, et al. Usability of the Massachusetts prescription drug monitoring program in the emergency department: A mixed-methods study. Acad Emerg Med. 2016;23(4):406-14.","DOI":"10.1111\/acem.12905"},{"key":"7793_CR20","doi-asserted-by":"crossref","unstructured":"Perez NM, Jennings WG, Wang Y, Delcher C. Law enforcement officers\u2019 perceptions of Florida\u2019s prescription drug monitoring program. J Contemp Crim Justice. 2017;33(4):368-79.","DOI":"10.1177\/1043986217724291"},{"key":"7793_CR21","doi-asserted-by":"crossref","unstructured":"Goodin AJ, Brown JD, Delcher C, Freeman PR, Talbert J, Henry SG, et al. Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Res Social Adm Pharm. 2020;16(9):1306-8.","DOI":"10.1016\/j.sapharm.2019.03.012"},{"key":"7793_CR22","unstructured":"National Center for Health Statistics. Centers for Disease Control and Prevention. 2019 National Electronic Health Records Survey (NEHRS) questionnaire. Available from: https:\/\/www.cdc.gov\/nchs\/nehrs\/questionnaires.htm."},{"key":"7793_CR23","unstructured":"National Center for Health Statistics. Centers for Disease Control and Prevention. 2019 National Electronic Health Records Survey (NEHRS) Public Use File Documentation (May 2021). Available from: https:\/\/www.cdc.gov\/nchs\/data\/nehrs\/NEHRS2019Doc-508.pdf."},{"key":"7793_CR24","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.; 2017.\u00a0https:\/\/www.stata.com\/support\/faqs\/resources\/citing-software-documentation-faqs\/."},{"key":"7793_CR25","doi-asserted-by":"crossref","unstructured":"Robinson A, Wilson MN, Hayden JA, Rhodes E, Campbell S, MacDougall P, et al. Health care provider utilization of prescription monitoring programs: a systematic review and meta-analysis. Pain Med. 2021.","DOI":"10.1093\/pm\/pnaa412"},{"key":"7793_CR26","doi-asserted-by":"crossref","unstructured":"Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff. 2017;36(4):733-41.","DOI":"10.1377\/hlthaff.2016.1141"},{"key":"7793_CR27","doi-asserted-by":"crossref","unstructured":"Lin H-C, Wang Z, Boyd C, Simoni-Wastila L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2018;76:348-54.","DOI":"10.1016\/j.addbeh.2017.08.032"},{"key":"7793_CR28","doi-asserted-by":"crossref","unstructured":"Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783-90.","DOI":"10.7326\/M17-3074"},{"key":"7793_CR29","doi-asserted-by":"crossref","unstructured":"Albright DL, McDaniel J, Laha-Walsh K, Morrison B, McIntosh S. Polysubstance abuse associated with more frequent opioid use among patients in rural primary care settings. J Opioid Manag. 2020;16(4):283-9.","DOI":"10.5055\/jom.2020.0582"},{"key":"7793_CR30","doi-asserted-by":"crossref","unstructured":"Van Rijswijk S, van Beek M, Schoof G, Schene A, Steegers M, Schellekens A. Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: a systematic review. Gen Hosp Psychiatry. 2019;59:37-50.","DOI":"10.1016\/j.genhosppsych.2019.04.008"},{"key":"7793_CR31","doi-asserted-by":"crossref","unstructured":"Matos A, Bankes DL, Bain KT, Ballinghoff T, Turgeon J. Opioids, polypharmacy, and drug interactions: a technological paradigm shift is needed to ameliorate the ongoing opioid epidemic. Pharmacy. 2020;8(3):154.","DOI":"10.3390\/pharmacy8030154"},{"key":"7793_CR32","doi-asserted-by":"crossref","unstructured":"Stogner JM, Sanders A, Miller BL. Deception for drugs: self-reported \u201cdoctor shopping\u201d among young adults. J Am Board Fam Med. 2014;27(5):583-93.","DOI":"10.3122\/jabfm.2014.05.140107"},{"key":"7793_CR33","doi-asserted-by":"crossref","unstructured":"Han H, Kass PH, Wilsey BL, Li CS. Increasing trends in Schedule II opioid use and doctor shopping during 1999\u20132007 in California. Pharmacoepidemiol Drug Saf. 2014;23(1):26-35.","DOI":"10.1002\/pds.3496"},{"key":"7793_CR34","unstructured":"Electronic Health Record Association. Prescription Drug Monitoring Programs & Electronic Prescribing of Controlled Substances State-By-State Landscape. (June 2018). Available from: https:\/\/www.ehra.org\/sites\/ehra.org\/files\/EHRA%20PDMP%20-%20EPCS%20-%20State%20Landscape%20June%202018.pdf"},{"key":"7793_CR35","unstructured":"Centers for Disease Control and Prevention. Overdose Data to Action. Available from: https:\/\/www.cdc.gov\/drugoverdose\/od2a\/index.html"},{"key":"7793_CR36","unstructured":"Centers for Disease Control and Prevention. Prevention for States. (2017) Available from: https:\/\/www.cdc.gov\/drugoverdose\/states\/state_prevention.html"},{"key":"7793_CR37","unstructured":"Flanigan, M. Electronic Clinical Decision Support (CDS) Tools that Support the Implementation of the CDC Guideline for Prescribing Opioids for Chronic Pain. Available from: https:\/\/oncprojectracking.healthit.gov\/wiki\/display\/TechLabSC\/Electronic+Clinical+Decision+Support+%28CDS%29+Tools+that+Support+the+Implementation+of+the+CDC+Guideline+for+Prescribing+Opioids+for+Chronic+Pain"},{"key":"7793_CR38","doi-asserted-by":"crossref","unstructured":"Strickler GK, Zhang K, Halpin JF, Bohnert AS, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019;199:1-9.","DOI":"10.1016\/j.drugalcdep.2019.02.010"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-022-07793-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:03:02Z","timestamp":1697155382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-022-07793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["7793"],"URL":"https:\/\/doi.org\/10.1007\/s11606-022-07793-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}